Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Dexamethasone
  • Multiple Myeloma
  • Oligopeptides
  • Thalidomide

abstract

  • In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).

authors

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1411321

PubMed ID

  • 25482145

Additional Document Info

start page

  • 142

end page

  • 52

volume

  • 372

number

  • 2